Rainier Acquisition Corporation

Rainier Acquisition Corporation

NNASDAQ:RNAQ
10.02
USD
+0.04
(+0.40%)
Rainier Acquisition Corporation
NASDAQ:RNAQ
(Nasdaq Stock Market)

Recent

price

10.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

USD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

USD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-100.29%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
63.71%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Rainier Acquisition Corporation is a Cayman Islands-domiciled special purpose acquisition company focused on identifying and partnering with category-defining life sciences companies to create long-term public-market value through scientific rigor, global sourcing and disciplined execution. Founded in 2023 and headquartered in New York, New York, the company operates through a unit structure that combines one Class A ordinary share and one-fourth of one redeemable warrant; its warrants are exercisable at $11.50 per share, and its securities trade on Nasdaq under the symbols RNAQU, RNAQ and RNAQW. The company’s strategy targets life sciences businesses across therapeutics, diagnostics, genomics, precision medicine, life-science tools and related healthcare technologies, with a focus on public and private market opportunities in the United States and other global markets. Recent company developments include the full exercise of the underwriter’s over-allotment option in its initial public offering, increasing total gross proceeds to $86.25 million, and the announced separation of its IPO units so that Class A ordinary shares and warrants can trade separately beginning September 15, 2026. The company is led by a management team and board with extensive experience in healthcare investing, capital markets, SPAC formation and biotechnology transactions, and it maintains its principal executive offices at 1 Penn Plaza, 48th Floor, New York, NY 10119.

Company News

  • Rainier Acquisition Corporation Announces Separation of Its Class A Ordinary Shares and Warrants on Nasdaq, Commencing September 14, 2026

  • Rainier Acquisition Corporation Announces Full Exercise of Over-Allotment Option, Bringing Total IPO Gross Proceeds to $86,250,000

  • Rainier Acquisition Corporation Announces Closing of $75,000,000 Initial Public Offering

  • Rainier Acquisition Corporation Announces Pricing of $75,000,000 Initial Public Offering